The DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
Current approaches to the treatment of Parkinson’s disease
Open accessAbstract
Enormous progress has been made in the treatment of Parkinson's disease (PD). As a result of advances in experimental therapeutics, many promising therapies for PD are emerging. Levodopa remains the most potent drug for controlling PD symptoms, yet is associated with significant complications such as the "wearing off" effect, levodopa-induced dyskinesias and other motor complications. Catechol-o-methyl-transferase inhibitors, dopamine agonists and nondopaminergic therapy are alternative modalities in the management of PD and may be used concomitantly with levodopa or one another. The neurosurgical treatment, focusing on deep brain stimulation, is reviewed briefly. Although this review has attempted to highlight the most recent advances in the treatment of PD, it is important to note that new treatments are not necessarily better than the established conventional therapy and that the treatment options must be individualized and tailored to the needs of each individual patient.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Parkinson's disease: clinical features and diagnosis
Jankovic, J. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.131045 · Cited by 5,720 · cited 3×
“Istradefylline, a novel adenosine antagonist, has been also reported to provide modest benefi t in PD patients with levodopa-related motor complications (Jankovic 2008b).”
Self-citationKrack, P., Batir, A., Van Blercom, N., Chabardes, S., Fraix, V., Ardouin, C., Koudsie, A., Limousin, P. D., Benazzouz, A., LeBas, J. F., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035275 · Cited by 2,249
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422004 · Cited by 1,539
Association between Early-Onset Parkinson's Disease and Mutations in the Parkin Gene
Lücking, C. B., Dürr, A., Bonifati, V., Vaughan, J., De Michele, G., Gasser, T., Harhangi, B. S., Meco, G., Denèfle, P., Wood, N. W., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005253422103 · Cited by 1,433
Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease
Gill, S. S., Patel, N. K., Hotton, G. R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D. J., Svendsen, C. N., & Heywood, P. (2003) · Nature Medicine · doi:10.1038/nm850 · Cited by 1,290
Rivastigmine for Dementia Associated with Parkinson's Disease
Emre, M., Aarsland, D., Albanese, A., Byrne, E. J., Deuschl, G., De Deyn, P. P., Durif, F., Kulisevsky, J., van Laar, T., Lees, A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041470 · Cited by 1,223
Reliability, validity, and clinical correlates of apathy in Parkinson's disease
(1992) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.4.2.134 · Cited by 1,185
Depression and Parkinson's disease: a review
(1992) · American Journal of Psychiatry · doi:10.1176/ajp.149.4.443 · Cited by 1,111
Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up
Rodriguez-Oroz, M. C., Obeso, J. A., Lang, A. E., Houeto, J.-L., Pollak, P., Rehncrona, S., Kulisevsky, J., Albanese, A., Volkmann, J., Hariz, M. I., et al. (2005) · Brain · doi:10.1093/brain/awh571 · Cited by 1,057
A Comparison of Continuous Thalamic Stimulation and Thalamotomy for Suppression of Severe Tremor
Schuurman, P. R., Bosch, D. A., Bossuyt, P. M. M., Bonsel, G. J., van Someren, E. J. W., de Bie, R. M. A., Merkus, M. P., & Speelman, J. D. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002173420703 · Cited by 1,044
Hallucinations in Parkinson's disease: Prevalence, phenomenology and risk factors
Fenelon, G. (2000) · Brain · doi:10.1093/brain/123.4.733 · Cited by 1,037
Effects of Coenzyme Q10 in Early Parkinson Disease: Evidence of Slowing of the Functional Decline
Shults, C. W. (2002) · Archives of Neurology · doi:10.1001/archneur.59.10.1541 · Cited by 984
Lang, A. E., Gill, S., Patel, N. K., Lozano, A., Nutt, J. G., Penn, R., Brooks, D. J., Hotton, G., Moro, E., Heywood, P., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20737 · Cited by 983
Valvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease
Zanettini, R., Antonini, A., Gatto, G., Gentile, R., Tesei, S., & Pezzoli, G. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa054830 · Cited by 884
Pathophysiology of the basal ganglia in Parkinson's disease
Obeso, J. A., Rodriguez-Oroz, M. C., Rodriguez, M., Lanciego, J. L., Artieda, J., Gonzalo, N., & Olanow, C. W. (2000) · Trends in Neurosciences · doi:10.1016/s1471-1931(00)00028-8 · Cited by 844
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study
Whone, A. L., Watts, R. L., Stoessl, A. J., Davis, M., Reske, S., Nahmias, C., Lang, A. E., Rascol, O., Ribeiro, M. J., Remy, P., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10609 · Cited by 829
Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD
Nutt, J. G., Burchiel, K. J., Comella, C. L., Jankovic, J., Lang, A. E., Laws, E. R., Lozano, A. M., Penn, R. D., Simpson, R. K., Stacy, M., et al. (2003) · Neurology · doi:10.1212/wnl.60.1.69 · Cited by 824
Self-citationParkinson Study Group (2002) · JAMA · doi:10.1001/jama.287.13.1653 · Cited by 711
Falling asleep at the wheel: Motor vehicle mishaps in persons taking pramipexole and ropinirole
Frucht, S., Rogers, J. D., Greene, P. E., Gordon, M. F., & Fahn, S. (1999) · Neurology · doi:10.1212/wnl.52.9.1908 · Cited by 692
Rascol, O., Brooks, D., Melamed, E., Oertel, W., Poewe, W., Stocchi, F., & Tolosa, E. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71083-7 · Cited by 641
Dyskinesias and motor fluctuations in Parkinson's disease
Schrag, A., & Quinn, N. (2000) · Brain · doi:10.1093/brain/123.11.2297 · Cited by 600
Pathological Gambling Caused by Drugs Used to Treat Parkinson Disease
Dodd, M. L., Klos, K. J., Bower, J. H., Geda, Y. E., Josephs, K. A., & Ahlskog, J. E. (2005) · Archives of Neurology · doi:10.1001/archneur.62.9.noc50009 · Cited by 563
Saint-Cyr, J. A. (2000) · Brain · doi:10.1093/brain/123.10.2091 · Cited by 554
Motor fluctuations and dyskinesias in Parkinson's disease: Clinical manifestations
Jankovic, J. (2005) · Movement Disorders · doi:10.1002/mds.20458 · Cited by 547
Self-citationFreezing of gait in PD: Prospective assessment in the DATATOP cohort
Giladi, N., McDermott, M. P., Fahn, S., Przedborski, S., Jankovic, J., Stern, M., Tanner, C., & The Parkinson Study Group (2001) · Neurology · doi:10.1212/wnl.56.12.1712 · Cited by 545
Self-citationPallidal vs Subthalamic Nucleus Deep Brain Stimulation in Parkinson Disease
Anderson, V. C., Burchiel, K. J., Hogarth, P., Favre, J., & Hammerstad, J. P. (2005) · Archives of Neurology · doi:10.1001/archneur.62.4.554 · Cited by 537
Miyasaki, J. M., Shannon, K., Voon, V., Ravina, B., Kleiner-Fisman, G., Anderson, K., Shulman, L. M., Gronseth, G., & Weiner, W. J. (2006) · Neurology · doi:10.1212/01.wnl.0000215428.46057.3d · Cited by 487
Drugs and Valvular Heart Disease
Roth, B. L. (2007) · New England Journal of Medicine · doi:10.1056/nejmp068265 · Cited by 479
Punding in Parkinson's disease: Its relation to the dopamine dysregulation syndrome
Evans, A. H., Katzenschlager, R., Paviour, D., O'Sullivan, J. D., Appel, S., Lawrence, A. D., & Lees, A. J. (2004) · Movement Disorders · doi:10.1002/mds.20045 · Cited by 474
Pluck, G. C. (2002) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.73.6.636 · Cited by 473
Anxiety disorders and depressive disorders preceding Parkinson's disease: A case-control study
Shiba, M., Bower, J. H., Maraganore, D. M., McDonnell, S. K., Peterson, B. J., Ahlskog, J. E., Schaid, D. J., & Rocca, W. A. (2000) · Movement Disorders · doi:10.1002/1531-8257(200007)15:4<669::aid-mds1011>3.0.co;2-5 · Cited by 465
(2005) · Archives of Neurology · doi:10.1001/archneur.62.2.241 · Cited by 418
The Occurrence of Depression in Parkinson's Disease: A Community-Based Study
Tandberg, E. (1996) · Archives of Neurology · doi:10.1001/archneur.1996.00550020087019 · Cited by 409
Punding in Parkinson's disease: Its relation to the dopamine dysregulation syndrome
Evans, A., Katzenschlager, R., Paviour, D. C., Appel‐Cresswell, S., Lawrence, A., & Lees, A. J. (2004) · UCL Discovery (University College London) · Cited by 401
Daytime sleepiness and other sleep disorders in Parkinson’s disease
Ondo, W. G., Dat Vuong, K., Khan, H., Atassi, F., Kwak, C., & Jankovic, J. (2001) · Neurology · doi:10.1212/wnl.57.8.1392 · Cited by 386
Self-citationEpidemiological, clinical, and genetic characteristics of early-onset parkinsonism
Schrag, A., & Schott, J. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70411-2 · Cited by 384
Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease
Wolozin, B., Wang, S. W., Li, N.-C., Lee, A., Lee, T. A., & Kazis, L. E. (2007) · BMC Medicine · doi:10.1186/1741-7015-5-20 · Cited by 383
Burchiel, K. J., Anderson, V. C., Favre, J., & Hammerstad, J. P. (1999) · Neurosurgery · doi:10.1097/00006123-199912000-00024 · Cited by 371
Neuropsychological changes between “off” and “on” STN or GPi stimulation in Parkinson’s disease
Pillon, B., Ardouin, C., Damier, P., Krack, P., Houeto, J. L., Klinger, H., Bonnet, A. M., Pollak, P., Benabid, A. L., & Agid, Y. (2000) · Neurology · doi:10.1212/wnl.55.3.411 · Cited by 332
Pathological gambling associated with dopamine agonist therapy in Parkinson’s disease
Driver-Dunckley, E., Samanta, J., & Stacy, M. (2003) · Neurology · doi:10.1212/01.wnl.0000076478.45005.ec · Cited by 313
Factors Associated With Dopaminergic Drug–Related Pathological Gambling in Parkinson Disease
Voon, V., Thomsen, T., Miyasaki, J. M., de Souza, M., Shafro, A., Fox, S. H., Duff-Canning, S., Lang, A. E., & Zurowski, M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.2.212 · Cited by 311
The impact of depressive symptoms in early Parkinson disease
Ravina, B., Camicioli, R., Como, P. G., Marsh, L., Jankovic, J., Weintraub, D., & Elm, J. (2007) · Neurology · doi:10.1212/01.wnl.0000268695.63392.10 · Cited by 301
Self-citationOndo, W. G., Tintner, R., Dat Voung, K., Lai, D., & Ringholz, G. (2005) · Movement Disorders · doi:10.1002/mds.20474 · Cited by 297
Comparative effects of unilateral and bilateral subthalamic nucleus deep brain stimulation
Kumar, R., Lozano, A. M., Sime, E., Halket, E., & Lang, A. E. (1999) · Neurology · doi:10.1212/wnl.53.3.561 · Cited by 290
Falling asleep whilst driving: are drivers aware of prior sleepiness?
Reyner, L. A., & Horne, J. A. (1998) · International Journal of Legal Medicine · doi:10.1007/s004140050131 · Cited by 289
Neuroprotection in Parkinson Disease: Mysteries, Myths, and Misconceptions
Schapira, A. H. V., & Olanow, C. W. (2004) · JAMA · doi:10.1001/jama.291.3.358 · Cited by 288
Anxiety disorders in patients with Parkinson's disease
(1990) · American Journal of Psychiatry · doi:10.1176/ajp.147.2.217 · Cited by 285
Bejjani, B.-P. (2000) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.68.5.595 · Cited by 281
Reading, P. J., Luce, A. K., & McKeith, I. G. (2001) · Movement Disorders · doi:10.1002/mds.1204 · Cited by 272
Ondo, W. G. (2005) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.065870 · Cited by 268
Ondo, W., Jankovic, J., Schwartz, K., Almaguer, M., & Simpson, R. K. (1998) · Neurology · doi:10.1212/wnl.51.4.1063 · Cited by 263
Self-citationAdvanced Parkinson disease treated with rotigotine transdermal system: PREFER Study
LeWitt, P. A., Lyons, K. E., & Pahwa, R. (2007) · Neurology · doi:10.1212/01.wnl.0000259516.61938.bb · Cited by 261
Rabey, J. M., Prokhorov, T., Miniovitz, A., Dobronevsky, E., & Klein, C. (2007) · Movement Disorders · doi:10.1002/mds.21116 · Cited by 259
No tissue damage by chronic deep brain stimulation in Parkinson's disease
Haberler, C., Alesch, F., Mazal, P. R., Pilz, P., Jellinger, K., Pinter, M. M., Hainfellner, J. A., & Budka, H. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200009)48:3<372::aid-ana12>3.0.co;2-0 · Cited by 258
Shoulson, I., Oakes, D., Fahn, S., Lang, A., Langston, J. W., LeWitt, P., Olanow, C. W., Penney, J. B., Tanner, C., Kieburtz, K., et al. (2002) · Annals of Neurology · doi:10.1002/ana.10191 · Cited by 258
Rektorová, I., Rektor, I., Bareš, M., Dostál, V., Ehler, E., Fanfrdlová, Z., Fiedler, J., Klajblová, H., Kulišt’ák, P., Ressner, P., et al. (2003) · European Journal of Neurology · doi:10.1046/j.1468-1331.2003.00612.x · Cited by 253
Kordower, J. H., Herzog, C. D., Dass, B., Bakay, R. A. E., Stansell, J., Gasmi, M., & Bartus, R. T. (2006) · Annals of Neurology · doi:10.1002/ana.21032 · Cited by 252
Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism
Chase, T. N., & Oh, J. D. (2000) · Trends in Neurosciences · doi:10.1016/s1471-1931(00)00018-5 · Cited by 251
Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease
Watts, R. L., Jankovic, J., Waters, C., Rajput, A., Boroojerdi, B., & Rao, J. (2007) · Neurology · doi:10.1212/01.wnl.0000252355.79284.22 · Cited by 249
Self-citation(2000) · Annals of Neurology · doi:10.1002/1531-8249(200001)47:1<2::aid-ana2>3.0.co;2-b · Cited by 249
Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk
Zhang, S. M., Hernán, M. A., Chen, H., Spiegelman, D., Willett, W. C., & Ascherio, A. (2002) · Neurology · doi:10.1212/01.wnl.0000028688.75881.12 · Cited by 240
Amantadine for Levodopa-Induced Dyskinesias: A 1-Year Follow-up Study
Metman, L. V., Del Dotto, P., LePoole, K., Konitsiotis, S., Fang, J., & Chase, T. N. (1999) · Archives of Neurology · doi:10.1001/archneur.56.11.1383 · Cited by 235
Longitudinal outcome of Parkinson’s disease patients with psychosis
Factor, S. A., Feustel, P. J., Friedman, J. H., Comella, C. L., Goetz, C. G., Kurlan, R., Parsa, M., Pfeiffer, R., & the Parkinson Study Group (2003) · Neurology · doi:10.1212/01.wnl.0000068010.82167.cf · Cited by 234
Stocchi, F., Vacca, L., Ruggieri, S., & Olanow, C. W. (2005) · Archives of Neurology · doi:10.1001/archneur.62.6.905 · Cited by 229
Manson, A. J., Turner, K., & Lees, A. J. (2002) · Movement Disorders · doi:10.1002/mds.10281 · Cited by 226
Characteristics of apathy in Parkinson's disease
Dujardin, K., Sockeel, P., Devos, D., Delliaux, M., Krystkowiak, P., Destée, A., & Defebvre, L. (2007) · Movement Disorders · doi:10.1002/mds.21316 · Cited by 219
Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease
Friedman, J. H., & Factor, S. A. (2000) · Movement Disorders · doi:10.1002/1531-8257(200003)15:2<201::aid-mds1001>3.0.co;2-d · Cited by 214
Medical Management of Levodopa-Associated Motor Complications in Patients with Parkinson???s Disease
Jankovic, J., & Stacy, M. (2007) · CNS Drugs · doi:10.2165/00023210-200721080-00005 · Cited by 213
Self-citationBeneficial effects of amantadine onL-dopa-induced dyskinesias in Parkinson's disease
Luginger, E., Wenning, G. K., B�sch, S., & Poewe, W. (2000) · Movement Disorders · doi:10.1002/1531-8257(200009)15:5<873::aid-mds1017>3.0.co;2-i · Cited by 203
A Controlled Trial of Rotigotine Monotherapy in Early Parkinson's Disease
(2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1721 · Cited by 203
Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up
Pietz, K., Hagell, P., & Odin, P. (1998) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.65.5.709 · Cited by 200
Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s disease
Breier, A., Sutton, V. K., Feldman, P. D., Kadam, D. L., Ferchland, I., Wright, P., & Friedman, J. H. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01392-6 · Cited by 198
Update on the pharmacology of REM sleep behavior disorder
Gagnon, J.-F., Postuma, R. B., & Montplaisir, J. (2006) · Neurology · doi:10.1212/01.wnl.0000233926.47469.73 · Cited by 196
Tolcapone and Hepatotoxic Effects
Olanow, C. W. (2000) · Archives of Neurology · doi:10.1001/archneur.57.2.263 · Cited by 173
Olanzapine treatment for dopaminergic‐induced hallucinations
Ondo, W. G., Levy, J. K., Vuong, K. D., Hunter, C., & Jankovic, J. (2002) · Movement Disorders · doi:10.1002/mds.10217 · Cited by 172
Self-citationSleepiness in Parkinson's disease: A controlled study
Brodsky, M. A., Godbold, J., Roth, T., & Olanow, C. W. (2003) · Movement Disorders · doi:10.1002/mds.10429 · Cited by 169
Tolcapone and fulminant hepatitis
Assal, F., Spahr, L., Hadengue, A., Rubbici-Brandt, L., & Burkhard, P. R. (1998) · The Lancet · doi:10.1016/s0140-6736(05)61511-5 · Cited by 167
Rich, S. S., Friedman, J. H., & Ott, B. R. (1995) · PubMed · Cited by 163
Dopamine agonists: their role in the treatment of Parkinson's disease
BROOKS, D. J. (2000) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.68.6.685 · Cited by 162
Wilkinson, D., Passmore, A., Bullock, R., Hopker, S., Smith, R., Potocnik, F., Maud, C., Engelbrecht, I., Hock, C., Ieni, Jr., et al. (2002) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2002.tb11294.x · Cited by 158
Neuroprotective and neurorestorative properties of GDNF
Gash, D. M., Zhang, Z., & Gerhardt, G. (1998) · Annals of Neurology · doi:10.1002/ana.410440718 · Cited by 158
Rater-blinded, Prospective Comparison
Merims, D., Balas, M., Peretz, C., Shabtai, H., & Giladi, N. (2006) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000236769.31279.19 · Cited by 156
Donepezil in the treatment of hallucinations and delusions in Parkinson’s disease
Fabbrini, G., Barbanti, P., Aurilia, C., Pauletti, C., Lenzi, G. L., & Meco, G. (2002) · Neurological Sciences · doi:10.1007/s100720200022 · Cited by 154
Anxiety disorders in Parkinson's disease.
Richard, I. H. (2005) · PubMed · Cited by 147
Williams-Gray, C. H., Foltynie, T., Lewis, S. J. G., & Barker, R. A. (2006) · CNS Drugs · doi:10.2165/00023210-200620060-00004 · Cited by 147
The effect of deep brain stimulation on quality of life in movement disorders
Diamond, A. L., & Jankovic, J. (2005) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.065334 · Cited by 147
Self-citationTen-year follow-up of three different initial treatments in de-novo PD
Lees, A. J., Katzenschlager, R., Head, J. A., & Ben‐Shlomo, Y. (2001) · Neurology · doi:10.1212/wnl.57.9.1687 · Cited by 143
"Panic attacks" in Parkinson's disease. A long-term complication of levodopa therapy.
Vázquez, A., Jiménez-Jiménez, F. J., Ruiz, P., & García-Urra, D. (1993) · PubMed · Cited by 142
A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson’s disease
Korczyn, A. D., Brunt, E. R., Larsen, J. O., Nagy, Z., Poewe, W. H., & Ruggieri, S. A. (1999) · Neurology · doi:10.1212/wnl.53.2.364 · Cited by 142
Disabling repetitive behaviors in Parkinson's disease
Kurlan, R. (2003) · Movement Disorders · doi:10.1002/mds.10625 · Cited by 142
Stover, N. P., Bakay, R. A. E., Subramanian, T., Raiser, C. D., Cornfeldt, M. L., Schweikert, A. W., Allen, R. C., & Watts, R. L. (2005) · Archives of Neurology · doi:10.1001/archneur.62.12.1833 · Cited by 140
Friedman, J. H., Berman, R., Goetz, C. G., Factor, S. A., Ondo, W. G., Wojcieszek, J., Carson, W. H., & Marcus, R. N. (2006) · Movement Disorders · doi:10.1002/mds.21091 · Cited by 138
Jankovic, J. J. (2007) · Archives of Neurology · doi:10.1001/archneur.64.5.676 · Cited by 135
Self-citationPunding prevalence in Parkinson's disease
Miyasaki, J. M., Hassan, K. T., Lang, A. E., & Voon, V. (2007) · Movement Disorders · doi:10.1002/mds.21296 · Cited by 131
Levodopa strengths and weaknesses
Jankovic, J. J. (2002) · Neurology · doi:10.1212/wnl.58.suppl_1.s19 · Cited by 131
Self-citationASSOCIATION BETWEEN EARLY-ONSET PARKINSON'S DISEASE AND MUTATIONS IN THE PARKIN GENE
Ücking, B. L., Onifati, V. I. B., Aughan, J. E. V., et al. (2000) · Cited by 129
Paroxetine in Parkinson’s disease: Effects on motor and depressive symptoms
Ceravolo, R., Nuti, A., Piccinni, A., Agnello, G., Bellini, G., Gambaccini, G., Osso, L. D., Murri, L., & Bonuccelli, U. (2000) · Neurology · doi:10.1212/wnl.55.8.1216 · Cited by 128
Clinical–Pathological study of levodopa complications
Rajput, A. H., Fenton, M. E., Birdi, S., Macaulay, R. J. B., George, D. H., Rozdilsky, B., Ang, L. C., Senthilselvan, A., & Hornykiewicz, O. (2002) · Movement Disorders · doi:10.1002/mds.10031 · Cited by 127
Stern, M. B., MAREK, K. L., Friedman, J. H., Hauser, R. A., LeWitt, P. A., Tarsy, D., & Olanow, C. W. (2004) · Movement Disorders · doi:10.1002/mds.20145 · Cited by 118
Entacapone in the treatment of Parkinson's disease
Schrag, A. E. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70098-3 · Cited by 116
SURGERY FOR MOVEMENT DISORDERS
Rezai, A. R., Machado, A. G., Deogaonkar, M. S., Azmi, H., Kubu, C. S., & Boulis, N. M. (2008) · Neurosurgery · doi:10.1227/01.neu.0000316285.52865.53 · Cited by 114
Treatment of Psychosis in Parkinson???s Disease: Safety Considerations
Fernandez, H. H., Trieschmann, M. E., & Friedman, J. H. (2003) · Drug Safety · doi:10.2165/00002018-200326090-00004 · Cited by 114
Apomorphine protects against MPTP-induced neurotoxicity in mice
Grünblatt, E., Mandel, S. A., Berkuzki, T., & Youdim, M. B. H. (1999) · Movement Disorders · doi:10.1002/1531-8257(199907)14:4<612::aid-mds1010>3.0.co;2-6 · Cited by 106
Hariz, M. I., Johansson, F., Shamsgovara, P., Johansson, E., Hariz, G., & Fagerlund, M. (2000) · Movement Disorders · Cited by 105
Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity
Zou, L., Jankovic, J. J., Rowe, D. B., Xie, W., Appel, S. H., & Le, W. (1999) · Life Sciences · doi:10.1016/s0024-3205(99)00062-4 · Cited by 105
Self-citationBotulinum toxin is a useful treatment in excessive drooling of saliva
Bhatia, K. P., Münchau, A. M., & Brown, P. (1999) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.67.5.697 · Cited by 102
Takeshita, S., Kurisu, K., Trop, L., Arita, K., Akimitsu, T., & Verhoeff, N. P. L. G. (2005) · Neurosurgical Review · doi:10.1007/s10143-005-0387-4 · Cited by 100
Are Dopamine Receptor Agonists Neuroprotective in Parkinson??s Disease?
Le, W., & Jankovic, J. J. (2001) · Drugs & Aging · doi:10.2165/00002512-200118060-00001 · Cited by 100
Self-citationContinuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa?
Nutt, J. G. (2006) · Movement Disorders · doi:10.1002/mds.21060 · Cited by 100
Postmortem analysis of bilateral subthalamic electrode implants in Parkinson's disease
Henderson, J. M., Pell, M. F., O'Sullivan, D. J., McCusker, E. A., Fung, V. S. C., Hedges, P., & Halliday, G. M. (2002) · Movement Disorders · doi:10.1002/mds.1261 · Cited by 98
Repetition, repetition, and repetition: Compulsive and punding behaviors in parkinson's disease
Voon, V. (2004) · Movement Disorders · doi:10.1002/mds.20046 · Cited by 97
Friedman, J. H. (1994) · Biological Psychiatry · doi:10.1016/0006-3223(94)90636-x · Cited by 95
da Silva‐Júnior, F. P., Braga‐Neto, P., Monte, F. S., & de Bruin, V. M. S. (2005) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2005.05.008 · Cited by 90
Effects of central dopaminergic stimulation by apomorphine on speech in Parkinson’s disease
Kompoliti, K., Wang, Q. E., Goetz, C. G., Leurgans, S. E., & Raman, R. (2000) · Neurology · doi:10.1212/wnl.54.2.458 · Cited by 88
Etminan, M., Gill, S. S., & Samii, A. (2003) · Drug Safety · doi:10.2165/00002018-200326060-00005 · Cited by 87
Watts, R. L., Raiser, C. D., Stover, N. P., Cornfeldt, M. L., Schweikert, A. W., Allen, R. C., Subramanian, T., Doudet, D. J., Honey, C. R., & Bakay, R. A. E. (2003) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-0643-3_14 · Cited by 85
Mirtazapine treats resting tremor, essential tremor, and levodopa-induced dyskinesias
Pact, V., & Giduz, T. (1999) · Neurology · doi:10.1212/wnl.53.5.1154-a · Cited by 84
Sleep and fatigue in Parkinson's disease
Friedman, J. H., & Chou, K. L. (2004) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2003.11.006 · Cited by 81
Surgery for Parkinson's Disease and Movement Disorders
Jankovic, J. J., Krauss, J. K., & Grossman, R. G. (2001) · Medical Entomology and Zoology · Cited by 79
Self-citationNakao, N., Nakai, E., Nakai, K., & Itakura, T. (1999) · Annals of Neurology · Cited by 76
Clinical Characteristics of Pramipexole-Induced Peripheral Edema
Tan, E., & Ondo, W. G. (2000) · Archives of Neurology · doi:10.1001/archneur.57.5.729 · Cited by 68
Use of Ziprasidone in Parkinsonian Patients With Psychosis
Gómez‐Esteban, J. C., Zarranz, J. J., Velasco, F., Lezcano, E., Lachen, M. C., Rouco, I., Bárcena, J., Boyero, S., Ciordia, R., & Allue, I. (2005) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000164297.91643.ff · Cited by 68
Tintner, R., Manian, P., Gauthier, P., & Jankovic, J. J. (2005) · Archives of Neurology · doi:10.1001/archneur.62.8.1290 · Cited by 65
Self-citationStimulation of the subthalamic nucleus in a patient with Parkinson disease and essential tremor.
Stover, N., Okun, M., Evatt, M., Raju, D., Bakay, R., & Vitek, J. (2005) · Archives of Neurology · doi:10.1001/archneur.62.1.141 · Cited by 64
Levodopa/carbidopa/entacapone (Stalevo)
Hauser, R. A. (2004) · Neurology · doi:10.1212/wnl.62.1_suppl_1.s64 · Cited by 63
Selegiline in de novo parkinsonian patients: The French selegiline multicenter trial (FSMT)
Allain, H., Cougnard, J., & Neukirch, H. C. (1991) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1991.tb05024.x · Cited by 60
Antiparkinsonian and antidepressant effects of high doses of bromocriptine
Jouvent, R., ABENSOUR, P., Bonnet, A. M., Widlöcher, D., Agid, Y., & Lhermitte, F. (1983) · Journal of Affective Disorders · doi:10.1016/0165-0327(83)90006-x · Cited by 57
Apomorphine can sustain the long-duration response to l -DOPA in fluctuating PD
Nutt, J. G., & Carter, J. H. (2000) · Neurology · doi:10.1212/wnl.54.1.247 · Cited by 49
The effects of subthalamic nucleus deep brain stimulation on parkinsonian tremor
Diamond, A. L., Shahed, J. J., & Jankovic, J. J. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.05.002 · Cited by 46
Self-citationHigh-Dose Ropinirole in Advanced Parkinson's Disease With Severe Dyskinesias
Cristina, S., Zangaglia, R., Mancini, F., Martignoni, E., Nappi, G., & Pacchetti, C. (2003) · Clinical Neuropharmacology · doi:10.1097/00002826-200305000-00008 · Cited by 43
Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson's disease
Lees, A. J., Ratziu, V., Tolosa, E., & Oertel, W. H. (2006) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.097154 · Cited by 43
Hallucinations in Parkinson's disease
Korczyn, A. D. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06230-4 · Cited by 40
Deprenyl effects on levodopa pharmacodynamics, mood, and free radical scavenging
Baronti, F., Davis, T. L., Boldry, R. C., Mouradian, M. M., & Chase, T. N. (1992) · Neurology · doi:10.1212/wnl.42.3.541 · Cited by 40
Jankovic, J. J. (2000) · Clinical Neuropharmacology · doi:10.1097/00002826-200009000-00003 · Cited by 37
Self-citationDual dopamine agonist treatment in Parkinson’s disease
Stocchi, F., Vacca, L., Berardelli, A., ONOFRJ, M. C., Manfredi, M., & Ruggieri, S. A. (2003) · Journal of Neurology · doi:10.1007/s00415-003-1086-0 · Cited by 35
Mancini, F., Tassorelli, C., Martignoni, E., Moglia, A., Nappi, G., Cristina, S., & Pacchetti, C. (2004) · Clinical Neuropharmacology · doi:10.1097/00002826-200401000-00010 · Cited by 31
Bonnet, A.-M. (2000) · CNS Drugs · doi:10.2165/00023210-200013050-00005 · Cited by 29
Jankovic, J. J. (2008) · Annals of Neurology · doi:10.1002/ana.21348 · Cited by 28
Self-citationClinical studies with transdermal rotigotine in early Parkinson’s disease
Poewe, W., & Luessi, F. (2005) · Neurology · doi:10.1212/wnl.65.2_suppl_1.s11 · Cited by 28
Neuroprotection in Parkinson Disease
Simpkins, N., & Jankovic, J. J. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.14.1650 · Cited by 25
Self-citationInitial Treatment of Parkinson Disease
Weiner, W. J. (2004) · Archives of Neurology · doi:10.1001/archneur.61.12.1966 · Cited by 24
Measuring motor complications in clinical trials for early Parkinson's disease
Marras, C., & Lang, A. E. (2003) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.74.2.143 · Cited by 24
Grandas, F., Hernandez, B., & on behalf of the PRACTICOMT Study Group (2007) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01635.x · Cited by 21
Neuroprotection for Parkinson’s disease
LeWitt, P. A. (2006) · Springer eBooks · doi:10.1007/978-3-211-33328-0_13 · Cited by 20
SURGERY FOR MOVEMENT DISORDERS
Gregory, R. P. (2002) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.72.suppl_1.i32 · Cited by 20
Management of the behavioral aspects of Parkinson’s disease
Borek, L. L., Chou, K. L., & Friedman, J. H. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.6.711 · Cited by 18
Dosing with ropinirole in a clinical setting
Korczyn, A. D., Thalamas, C., & Adler, C. H. (2002) · Acta Neurologica Scandinavica · doi:10.1034/j.1600-0404.2002.01343.x · Cited by 16
Dopamine agonists modify the course of Parkinson disease.
Stern, M. (2004) · Archives of Neurology · doi:10.1001/archneur.61.12.1969 · Cited by 15
Intervening in the neuropsychiatric features of Parkinson’s disease
Weintraub, D. A., & Stern, M. B. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.6.699 · Cited by 5
Cited by
Maiti, P., Manna, J., & Dunbar, G. L. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0099-z · Cited by 525
Gadhave, D. G., Sugandhi, V. V., Jha, S. K., Nangare, S. N., Gupta, G., Singh, S. K., Dua, K., Cho, H., Hansbro, P. M., & Paudel, K. R. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102357 · Cited by 358
Diametric neural ensemble dynamics in parkinsonian and dyskinetic states
Parker, J. G., Marshall, J. D., Ahanonu, B., Wu, Y.-W., Kim, T. H., Grewe, B. F., Zhang, Y., Li, J. Z., Ding, J. B., Ehlers, M. D., et al. (2018) · Nature · doi:10.1038/s41586-018-0090-6 · Cited by 349
Clinical Features of Parkinson’s Disease: The Evolution of Critical Symptoms
Váradi, C. (2020) · Biology · doi:10.3390/biology9050103 · Cited by 196
Recent Advancements of Nanomedicine in Neurodegenerative Disorders Theranostics
Mukherjee, S., Madamsetty, V. S., Bhattacharya, D., Roy Chowdhury, S., Paul, M. K., & Mukherjee, A. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202003054 · Cited by 152
Metadata
- Authors
- Jankovic, J.
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2008-09
- Volume
- 4
- Issue
- 4
- Pages
- 743
- ISSN
- 1176-6328 (ISSN-L)
- OpenAlex
- W1984879946
- Cited by
- 342
- References
- 150
- FWCI
- 3.14
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.